Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

August 12, 2013 updated by: Vessix Vascular, Inc

Minnow Medical GRST Peripheral Catheter System First-in-Man Study Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

The purpose of this study is to evaluate the safety and efficacy of the Minnow Medical GRST Peripheral Catheter System in the treatment of new lesions in the superficial femoral artery or the popliteal artery.

Study Overview

Status

Withdrawn

Study Type

Interventional

Phase

  • Phase 2
  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient is ≥18 years of age
  • Patient is Rutherford category 2-4
  • De novo lesion in the SFA or popliteal artery with a diameter stenosis ≥50%
  • Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%
  • Target lesion stenosis has a length of ≤100 mm based on visual assessment
  • Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment
  • Angiographic evidence of distal runoff defined as minimum one (1) patent tibial artery with a straight flow to the foot
  • Patient is willing and able to provide written informed consent prior to any study specific procedure
  • Patient is willing and able to comply with specified follow-up evaluations at the specified times

Exclusion Criteria:

  • Any prior intervention in the intended target lesion including 10 mm proximal or distal from the intended treatment area
  • Evidence of thrombus in the target vessel
  • Prior ipsilateral or contralateral lower limb arterial bypass
  • Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure
  • Target lesion is severely calcified
  • Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
  • Any planned surgery within 30 days of the study procedure.
  • Renal failure (serum creatinine > 2.0 mg/dL)
  • Female with childbearing potential without a negative pregnancy test
  • Patient has had an organ transplant
  • Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study
  • In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
GRST Peripheral Catheter System
Treatment to dilate stenoses and reduce plaque in treated vessels

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Major adverse clinical events rate
Time Frame: Up to 30 days
Up to 30 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Binary restenosis
Time Frame: 30 days, 3 months, 6 months
30 days, 3 months, 6 months
Target lesion revascularization
Time Frame: 30 days, 3 months, 6 months
30 days, 3 months, 6 months
Amputation rate
Time Frame: 30 days, 3 months, 6 months
30 days, 3 months, 6 months
Technical success
Time Frame: Treatment
Treatment
Serious adverse events rate, including major adverse clinical events
Time Frame: 30 days, 3 months, 6 months
30 days, 3 months, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dierk Scheinert, MD, Universität Leipzig Herzzentrum

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2007

Primary Completion (Actual)

November 1, 2010

Study Completion (Actual)

May 1, 2011

Study Registration Dates

First Submitted

September 9, 2008

First Submitted That Met QC Criteria

September 9, 2008

First Posted (Estimate)

September 11, 2008

Study Record Updates

Last Update Posted (Estimate)

August 14, 2013

Last Update Submitted That Met QC Criteria

August 12, 2013

Last Verified

August 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe